REUTERS/Mike Blake/File PhotoAug 9 (Reuters) - Illumina Inc (ILMN.O) cut annual profit forecast, in a sign that a funding crunch among its biotech and pharmaceutical clients is expected to weigh on sales for its genetic testing tools and diagnostics products.
Rising interest rates have squeezed funding for drug development and research programs among small biotech firms, especially in China.
Higher-than-estimated demand for the production-scale sequencer, NovaSeq X, however, helped the U.S. genetic testing company surpass Wall Street estimates for second-quarter profit.
The San Diego, California-based company reported adjusted profit of 32 cents per share, compared with expectations of 2 cents per share, according to Refinitiv data.
Illumina expects full-year adjusted profit per share to be between $0.75 and $0.90, compared with its prior forecast of $1.25 to $1.50.
Persons:
Mike Blake, Charles Dadswell ., Illumina, Carl Icahn, Francis deSouza, Pratik Jain, Shilpi Majumdar
Organizations:
Inc, REUTERS, Illumina, Bank, Wall, Thomson
Locations:
San Diego , California, China, U.S, Bengaluru